Autolus Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 376
Employees
  • Stock Symbol
  • AUTL
Stock Symbol
  • Share Price
  • $3.96
  • (As of Friday Closing)

Autolus General Information

Description

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises five programs: AUTO1, AUTO1/22, AUTO3, AUTO4 and AUTO6. The company operates in two geographic regions, the United Kingdom and the United States.

Contact Information

Website
www.autolus.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • The Mediaworks, 191 Wood Lane
  • White City
  • London W12 7RZ
  • England, United Kingdom
+44 020 0000 0000

Autolus Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Autolus Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.96 $4.14 $3.92 - $9.12 $302M 72.9M 1.23M -$2.29

Autolus Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 30-Sep-2018
EV 282,793 342,726 391,090 1,110,847
Revenue 1,507 242 0 0
EBITDA (75,487) (75,793) (136,939) (51,854)
Net Income (143,291) (142,094) (123,849) (44,751)
Total Assets 296,636 294,237 303,533 273,205
Total Debt 21,810 54,161 26,221 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Autolus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial

Autolus Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the t
Biotechnology
London, United Kingdom
376 As of 2020
00000
000000000 00000

0000 000

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

00000000

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000 000000000
Abingdon, United Kingdom
000 As of 0000
00000
0.00 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Autolus Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AVEO Oncology Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
0000000000 Formerly VC-backed Abingdon, United Kingdom 000 00000 00000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000000 Formerly VC-backed Planegg, Germany 00 00000 000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
You’re viewing 5 of 27 competitors. Get the full list »

Autolus Patents

Autolus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3131839-A1 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car Pending 08-Mar-2019 000000000
AU-2020235395-A1 Compositions and methods comprising engineered chimeric antigen receptor and modulator of car Pending 08-Mar-2019 000000000
GB-201901187-D0 Treatment of neurotoxicity and/or cytokine release syndrome Ceased 29-Jan-2019 00000000000
US-20200200756-A1 Methods Pending 21-Dec-2018 000000000000 0
GB-201816644-D0 Vectors Ceased 12-Oct-2018 A61K39/0011
To view Autolus’s complete patent history, request access »

Autolus Executive Team (16)

Name Title Board Seat Contact Info
Christian Itin Ph.D Chief Executive Officer & Chairman
Andrew Oakley Chief Financial Officer, Finance & Senior Vice President
Christopher Vann Chief Operating Officer, Operations & Senior Vice President
David Brochu Chief Technology Officer, Technology & Senior Vice President
Edgar Braendle Ph.D Chief Development Officer
You’re viewing 5 of 16 executive team members. Get the full list »

Autolus Board Members (11)

Name Representing Role Since
Christian Itin Ph.D Autolus Chief Executive Officer & Chairman 000 0000
Cynthia Butitta Autolus Board Member 000 0000
Jay Backstrom MD Self Board Member 000 0000
John Berriman Self Board Member 000 0000
John Johnson Self Chairman of Board of Directors 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Autolus Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Autolus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Autolus‘s full profile, request access.

Request a free trial